In-situ Cytokines Expression in the CNS in Amyotrophic Lateral Sclerosis (ALS)
- Conditions
- Amyotrophic Lateral Sclerosis
- Registration Number
- NCT02582385
- Lead Sponsor
- Brugmann University Hospital
- Brief Summary
The investigators aim at exploring the differential/topographical in-situ expression of cytokines in the central nervous system (CNS) of patients who died with amyotrophic lateral sclerosis (ALS), using archived histopathology slides and residual paraffin blocks from autopsied cases. Previous studies from the investigators and other groups showed that inflammatory cytokines are implicated in several neurological affections, particularly neurodegenerative conditions. However, in-situ cytokine expression has never been studied so far in ALS. The investigators wanted to see if these neuro-mediators are involved in the neuromolecular chain/cascade underlying ALS.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 5
- patients who died with amyotrophic lateral sclerosis, having been autopsied.
- N/A
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method in situ cytokine detection: interleukin 18 retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 IHC detection on histopathology sections of paraffin embedded brain tissue.
in situ cytokine detection: interleukin 1 retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 IHC detection on histopathology sections of paraffin embedded brain tissue.
in situ cytokine detection: interleukin 6 retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 IHC detection on histopathology sections of paraffin embedded brain tissue.
in situ cytokine detection:TNF-a retrospective study performed on archived paraffin blocks, autopsies performed between 2000 and 2005 IHC detection on histopathology sections of paraffin embedded brain tissue.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
CHU Brugmann
🇧🇪Brussels, Belgium
CHU Brugmann🇧🇪Brussels, Belgium
